PERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: A translational subgroup analysis from AIO-PK0104

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ormanns, Steffen ^a   Siveke, Jens T ^b   Heinemann, Volker ^c,d   Haas, Michael ^c   Sipos, Bence ^e   Schlitter, Anna M ^f   Esposito, Irene ^f   Jung, Andreas ^a,d   Laubender, Rüdiger P ^a,d   Kruger, Stephan ^c   Vehling Kaiser, Ursula ^g   Winkelmann, Cornelia ^h   Fischer von Weikersthal, Ludwig ⁱ   Clemens, Michael R ^j   Gauler, Thomas C ^k   Märten, Angela ^l   Geissler, Michael ^m   Greten, Tim F ⁿ   Kirchner, Thomas ^a,d   Boeck, Stefan ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g Practice for Medical Oncology   (Germany)

^h Krankenhaus Lutherstadt Wittenberg   (Germany)

ⁱ Gesundheitszentrum St Marien GmbH   (Germany)

^j Department of Internal Medicine I   (Germany)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m KLINIKUM ESSLINGEN   (Germany)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Biomarker; EGFR; Erlotinib; Pancreatic cancer

Indexed keywords

ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; TUMOR MARKER; EIF2AK3 PROTEIN, HUMAN; PROTEIN KINASE R; QUINAZOLINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; SCORING SYSTEM; TRANSLATIONAL RESEARCH; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PHOSPHORYLATION; SURVIVAL; YOUNG ADULT;

ADULT; EIF-2 KINASE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84906832505     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-624     Document Type: Article

References (27)

1. Verslype C, van Cutsem E, Dicato M, Arber N, Berlin JD, Bu¨chler MW, Cervantes A, Ciardiello F, Ducreux M, Douillard JY, Grothey A, Haller D, Haustermans K, Heinemann V, Hidalgo M, Labianca R, Li J, Marshall JL, Nordlinger B, O'Reilly EM, Roth A, Rougier P, Ryan D, Schmiegel W, Seufferlein T, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, van Laethem JL, Ychou M, Zalcberg J. The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012. Ann Oncol 2013, 24(suppl 4):iv5-iv10.
2. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013, 144:1316-1326.
3. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012, 38:843-853.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 2007, 25:1960-1966.
5. Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TR, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013, 31:4453-4461.
6. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
7. Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Ma¨rten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Ho¨hler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013, 62:751-759.
8. Ogura T, Yamao K, Hara K, Mizuno N, Hijioka S, Imaoka H, Sawaki A, Niwa Y, Tajika M, Kondo S, Tanaka T, Shimizu Y, Bhatia V, Higuchi K, Hosoda W, Yatabe Y. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 2013, 48:640-646.
9. Kim ST, Lim do H, Jang KT, Lim T, Lee J, Choi YL, Jang HL, Yi JH, Baek KK, Park SH, Park YS, Lim HY, Kang WK, Park JO. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 2011, 10:1993-1999.
10. Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Ma¨rten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer 2013, 108:469-476.
11. Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Ormanns S, Haas M, Modest DP, Kirchner T, Heinemann V. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. J Gastroenterol 2013, 48:544-548.
12. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol 2007, 14:2150-2158.
13. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002, 1:777-783.
14. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012, 2:685-693.
15. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004, 10:2846-2850.
16. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006, 13:933-939.
17. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol 2007, 14:3527-3533.
18. Ardito CM, Gru¨ner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.
19. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One 2012, 7:e43192.
20. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:2622-2629.
21. Da Cunha SG, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010, 116:5599-5607.
22. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010, 28:3605-3610.
23. Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M. Overexpression of p53 protein in human tumors. Med Mol Morphol 2012, 45:115-123.
24. Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Brown G, Chau I. TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial. Eur J Cancer 2013, 49(suppl 2). abstract #7.
25. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res 2013, 19:538-540.
26. Conroy T, Desseigne F, Ychou M, Bouche´ O, Guimbaud R, Be´couarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardie`re C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pe´re´-Verge´ D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, . Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup.
27. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691-1703.